• Article highlight
  • Article tables
  • Article images

Article History

Received : 25-04-2023

Accepted : 24-06-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 524

PDF Downloaded: 290


Get Permission Das, Gupta, and Das: A case report on sero-negative juvenile idiopathic arthritis progressing to polyarthritis


Introduction

The most prevalent chronic rheumatic condition in children, juvenile idiopathic arthritis (JIA), has an unclear cause. Estimating that 20% of JIA populations have Polyarthritis, approximately 85% of the polyarthritis populations have Rheumatoid Factor (RF)- Negative.1, 2 Annual incidence & prevalence for RF negative polyarthritis can be estimated as 1 to 4 per 100,000 and 21 to 37 per 100,000 respectively. 3 RF negative Polyarthritis girls are affected 4 times more frequently than the boys.4 JIA includes a number of distinct subgroups and typically manifests as peripheral arthritis. There are many different clinical states on the illness spectrum. It has been demonstrated that both endogenous and external antigens with heightened inflammatory responses are crucial in the pathophysiology of the illness. The patient's daily activities and productivity are restricted by chronic inflammation. In order to be diagnosed with JIA, a patient must have the disease's inception before the age of 16 years where there is biphasic peak of onset, one at 1-4 years & other at later childhood & adolescence and have arthritis that has persisted for more than six weeks.4, 5, 6 Juvenile rheumatoid arthritis (JRA) and juvenile chronic arthritis (JCA) are other names that have been used for the same clinical entity. 7 There is symmetric involvement of joints.

Case Report

History

17 Years/Female patient presented at our OPD with complaints of:-

  1. Multiple joint pain since 1.5 years

  2. Patient could not able to mobilize on her own on presentation

  3. There is history of exacerbation

  4. Fever On & Off

    1. She is 2nd Born Child

    2. There is no history of similar illness in any of her family members or 1st & 2nd degree relatives.

Physical & clinical examination

  1. Diffuse swelling present over Bilateral Wrists, Knee & Ankle

  2. On Examination of Bilateral Hip :

Fixed Flexion Deformity (FFD) of 20 degrees & Fixed Abduction Deformity of 15 degrees present on Right Hip

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/a9a6be98-d237-4bb6-9e0b-79d8e6bc9b57image1.jpg
Figure 2
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/a9a6be98-d237-4bb6-9e0b-79d8e6bc9b57image2.jpg

   

Management

Blood investigations

  1. Complete Blood Count (CBC) - Normal

  2. C-Reactive Protein (CRP) - Negative

  3. Erythrocyte Sedimentation Rate - 70 mm AEFH (Raised)

  4. RA Factor – Negative

  5. Anti-cyclic citrullinated peptide (Anti-CCP) – Negative

  6. Anti Nuclear Antibody (ANA) – Negative

Roentgenographic examination

  1. On Xray of Hand :- Soft tissue swelling, osteopenia, Loss of articular cartilage & destructive changes in the distal & proximal interphalangeal (i.e. DIP & PIP) joints and metacarpophalangeal (MCP) joints (Figure 3)

  2. On Xray of Wrist:- Erosions at the radial articular surface & metacarpal bases with crenated margins with destruction and fusion of carpal bones in the wrist (Figure 3)

  3. On Xray of Cervical Spine:- Ankylosis, Loss of normal cervical lordosis, Narrowing & erosion of neural arch joints (Figure 4)

  4. On Xray of Bilateral Hip with Pelvis:- Uniform joint space narrowing with Destruction of femoral head & acetabula, fusion of Sacro-Iliac joint (Figure 5)

  5. On Xray of Bilateral Knee Joint:- Soft tissue swelling , Osteopenia , Joint space narrowing (Figure 6)

Figure 3

1,2,Radiographs at onset, 3 Radiographs after 6 month

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/a9a6be98-d237-4bb6-9e0b-79d8e6bc9b57image3.png
Figure 4
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/a9a6be98-d237-4bb6-9e0b-79d8e6bc9b57image4.jpeg
Figure 5
https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/e5d80762-6d8d-4d21-98df-721241af0e96/image/fa5c3214-48ad-4b52-9800-a4a5865d8ff6-u1.png
Figure 6
https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/e5d80762-6d8d-4d21-98df-721241af0e96/image/29822652-6b3e-4f75-9335-018658f1bb19-u1.png

Treatment

  1. Non- Steroidal Anti-inflammatory Drugs: 8, 9

    1. Tab. Naproxen 250 mg: 1 tab twice daily after food * 5days & then SOS in case of pain.

  2. Disease - Modifying Anti-Rheumatic Drugs (DMARDs): 10, 9, 11

    1. Tab. Methotrexate 15 mg: 1 tab once weekly after food.

    2. Tab. Sulfasalazine: Initially 1 tab (500 mg) twice daily after food * 7 days.

  3. Tab. Folic Acid 5 mg: 1 tab once daily except on the day of taking Methotrexate. 10, 8

  4. Tab. Deflazacort 6mg: 8, 9, 121 tab (12mg) once daily after food * 4 monthsThen, 1 tab (6mg) once daily after food * 4 monthsThen, 1 tab (6mg) on alternative day after food * 4 months & then STOP.* Before starting DMARD therapy, LFT, KFT, CXR (PAV), Virology were done.* After every 12 weeks of above treatment LFT, KFT are being repeated to monitor the side-effects of DMARDs.

Follow – Up

The patient is reviewed at 4 weeks interval to know the disease progression. On Follow-up at 4 weeks, there is decreased ESR (40 mm AEFH), CRP Negative. The symptoms has subsided than before. The patient is also reviewed on every 12 weeks intervals to rule out progression to Sero positive adult Rheumatoid arthritis factor. The patient is also being monitored for the adverse effects of the drugs causing hepatic & renal impairment because of DMARDs.

Conclusion

The importance of early recognition of clinical features in the diagnosis allows correct treatment, planning & reduces the chance of disease progression & complications in future, thus ensuring a better quality of life to the patient. It allows aggressive treatment to prevent irreversible joint damage. As a result, it helps patient to live a healthy life.

Conflict of Interest

None.

Source of Funding

None.

References

1 

RK Saurenmann JB Rose P Tyrrell RM Laxer R Schneider ED Silverman Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factorArthritis Rheum200756619748410.1002/art.22709

2 

N Adib K Hyrich J Thornton Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective StudyRheumatology (Oxford)20084779915

3 

KG Oen M Cheang Epidemiology of chronic arthritis in childhoodSemin Arthritis Rheum199626357591

4 

A G Greenwald A Zakerzadeh R M Laxer Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient groupClin Exp Rheumatol201331464552

5 

G Giancane A Consolaro S Lanni S Davi B Schiappapietra A Ravelli Juvenile Idiopathic Arthritis: Diagnosis and TreatmentRheumatol Ther20163218720710.1007/s40744-016-0040-4

6 

M Aslan O Kasapcopur H Yasar E Polat S Saribas H Cakan Do infections trigger juvenile idiopathic arthritis?Rheumatol Int20113122152010.1007/s00296-009-1253-4

7 

RE Petty LR Wedderburn RE Petty RM Laxer CB Lindsley LR Wedderburn Juvenile Idiopathic ArthritisTextbook of Pediatric Rheumatology2016Elsevier Saunders Company188284

8 

Ö Kasapçopur K Barut Treatment in juvenile rheumatoid arthritis and new treatment optionsTurk Pediatri Ars201550111010.5152/tpa.2015.2229

9 

B Makay E Unsal O Kasapcopur Juvenile idiopathic arthritisWJR World201331624

10 

JE Weiss NT Ilowite Juvenile idiopathic arthritisPediatr Clin North Am20055224134210.1016/j.pcl.2005.01.007

11 

B Hügle G Horneff The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritisExpert Opin Pharmacother20161757031410.1517/14656566.2016.1133592

12 

A Ravelli B Lattanzi A Consolaro A Martini Glucocorticoids in paediatric rheumatologyClin Exp Rheumatol201129514852



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.